Complicated atazanavir-associated cholelithiasis: A report of 14 cases

Clinical Infectious Diseases

Volumn 55, Issue 9, 2012, Pages 1270-1272

  Rakotondravelo, Soloniaina ^a   Poinsignon, Yves ^a   Borsa Lebas, Françoise ^c   De La Blanchardière, Arnaud ^f   Michau, Christophe ^g   Jantzem, Hélène ^d   Massy, Nathalie ^d   Polard, Elisabeth ^d   Giroux, Fanny ^b   Kerspern, Hélène ^h   Meskar, Ahmed ^h   Hue, Guy ^e   Tribut, Olivier ⁱ   Arvieux, Cédric ^j   Tattevin, Pierre ^j  

^a Centre Hospitalier Bretagne Atlantique   (France)

^b Biochimie   (France)

^c Maladies Infectieuses   (France)

^d Centre Régional de Pharmaco Vigilance   (France)

^e HÔPITAL CHARLES NICOLLE   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g CENTRE HOSPITALIER   (France)

^h BREST UNIVERSITY HOSPITAL   (France)

ⁱ Pharmacologie ^*  (France)

^j PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; RITONAVIR;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CHOLECYSTECTOMY; CHOLELITHIASIS; CLINICAL ARTICLE; ENDOSCOPIC SPHINCTEROTOMY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFRARED SPECTROMETRY; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CALCULI; CHOLELITHIASIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; SPECTROPHOTOMETRY, INFRARED;

EID: 84867558887     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis620     Document Type: Article

References (10)

1. Martindale: the complete drug reference. 37th ed. London: Pharmaceutical Press, 2011.
2. Bristol-Myers Squibb. Reyataz (atazanavir sulfate): full prescription information [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2011.
3. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavirboosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25:1671-3.
4. Jacques AC, Giguere P, Zhang G, Touchie C, la Porte CJ. Atazanavirassociated choledocholithiasis leading to acute hepatitis in an HIVinfected adult. Ann Pharmacother 2010; 44:202-6.
5. Courbon E, Laylavoix F, Soulie C, et al. Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient. J Antimicrob Chemother 2012; 67:250-1.
6. Estepa L, Daudon M. Contribution of Fourier transform infrared spectroscopy to the identification of urinary stones and kidney crystal deposits. Biospectroscopy 1997; 3:347-69. (Pubitemid 127781310)
7. Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin North Am 2010; 39:157-69, vii. 8. Erlinger S. Drug-induced cholestasis. J Hepatol 1997; 26(Suppl 1):1-4.
8. Siveke JT, Bogner Jr. Cholelithiasis possibly induced by protease inhibitors in 3 patients. Clin Infect Dis 2003; 36:1498-500. (Pubitemid 36702888)
9. Verdon R, Daudon M, Albessard F, Brefort JL, Bazin C. Indinavirinduced cholelithiasis in a patient infected with human immunodeficiency virus. Clin Infect Dis 2002; 35:e57-9.
10. Park WB, Choe PG, Song KH, et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1 28 allele frequency. Clin Infect Dis 2010; 51:101-6.